Drugs / roginolisib
roginolisib
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07203391 | Feb 2026 → Dec 2027 expected | uveal melanoma | St Vincent's Hospital, Sydney | Recruiting | No outcome recorded |
| Phase 1 | NCT04328844 | Feb 2020 → Dec 2023 overdue | myelofibrosis, non-Hodgkin lymphoma, non-small cell lung carcinoma, uveal melanoma | iOnctura | Active not recruiting | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT06887803 | Nov 2025 → Mar 2028 expected | myelofibrosis | iOnctura | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07018752 | Aug 2025 → Apr 2028 expected | peripheral T-cell lymphoma, not otherwise specified | The Lymphoma Academic Research Organisation | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06879717 | Apr 2025 → Jan 2027 expected | non-small cell lung carcinoma | iOnctura | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06644183 | Mar 2025 → Oct 2028 expected | B-cell chronic lymphocytic leukemia | Jennifer R. Brown, MD, PhD | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06717126 | Feb 2025 → Dec 2027 expected | uveal melanoma | iOnctura | Active not recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Roginolisib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06887803 ↗ |
| Known as | IOA-244 | “A Phase I/IIa open-label, randomised study of oral roginolisib (IOA-244 \[roginolisib hemi-fumarate\]) in combination with dostarlimab with or without docetaxel in Advanced Non...” NCT06879717 ↗ |
| Known as | MSC2360844 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3683575 ↗ |
| Known as | roginolisib hemi-fumarate | “A Phase I/IIa open-label, randomised study of oral roginolisib (IOA-244 \[roginolisib hemi-fumarate\]) in combination with dostarlimab with or without docetaxel in Advanced Non...” NCT06879717 ↗ |
| Action | Inhibit | “A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers” NCT04328844 ↗ |
| Modality | Small molecule | — CHEMBL3683575 ↗ |
| Route | Oral | “IOA-244 will be administered orally once daily (QD)” NCT04328844 ↗ |